Common	O
and	O
Rare	O
Variant	O
Analysis	O
in	O
Early	O
-	O
Onset	O
Bipolar	B-DS
Disorder	I-DS
Vulnerability	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
SJ	O
M	O
.	O

Leboyer	O
FB	O
BE	O
M	O
.	O

Lathrop	O
.	O

Performed	O
the	O
experiments	O
:	O
SJ	O
LC	O
JD	O
AN	O
AH	O
FD	O
LP	O
AB	O
.	O

Analyzed	O
the	O
data	O
:	O
SJ	O
SC	O
BE	O
TWM	O
NZ	O
LC	O
FD	O
MM	O
LP	O
FM	O
DZ	O
IG	O
SH	O
TGS	O
MH	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
BE	O
AG	O
JPK	O
CH	O
IG	O
SH	O
M	O
.	O

Lathrop	O
WM	O
MA	O
MR	O
TGS	O
FJM	O
JRK	O
NC	O
MMN	O
FB	O
M	O
.	O

Leboyer	O
.	O

Wrote	O
the	O
paper	O
:	O
SJ	O
SC	O
BE	O
TWM	O
TGS	O
MH	O
NC	O
FB	O
M	O
.	O

Leboyer	O
.	O

Bipolar	B-DS
disorder	I-DS
is	O
one	O
of	O
the	O
most	O
common	O
and	O
devastating	O
psychiatric	B-DS
disorders	I-DS
whose	O
mechanisms	O
remain	O
largely	O
unknown	O
.	O

Despite	O
a	O
strong	O
genetic	O
contribution	O
demonstrated	O
by	O
twin	O
and	O
adoption	O
studies	O
,	O
a	O
polygenic	O
background	O
influences	O
this	O
multifactorial	O
and	O
heterogeneous	O
psychiatric	B-DS
disorder	I-DS
.	O

To	O
identify	O
susceptibility	O
genes	O
on	O
a	O
severe	O
and	O
more	O
familial	O
sub	O
-	O
form	O
of	O
the	O
disease	O
,	O
we	O
conducted	O
a	O
genome	O
-	O
wide	O
association	O
study	O
focused	O
on	O
211	O
patients	O
of	O
French	O
origin	O
with	O
an	O
early	O
age	O
at	O
onset	O
and	O
1	O
,	O
719	O
controls	O
,	O
and	O
then	O
replicated	O
our	O
data	O
on	O
a	O
German	O
sample	O
of	O
159	O
patients	O
with	O
early	O
-	O
onset	O
bipolar	B-DS
disorder	I-DS
and	O
998	O
controls	O
.	O

Replication	O
study	O
and	O
subsequent	O
meta	O
-	O
analysis	O
revealed	O
two	O
genes	O
encoding	O
proteins	O
involved	O
in	O
phosphoinositide	O
signalling	O
pathway	O
(	O
PLEKHA5	B-GP
and	O
PLCXD3	B-GP
).	O

We	O
performed	O
additional	O
replication	O
studies	O
in	O
two	O
datasets	O
from	O
the	O
WTCCC	O
(	O
764	O
patients	O
and	O
2	O
,	O
938	O
controls	O
)	O
and	O
the	O
GAIN	O
-	O
TGen	O
cohorts	O
(	O
1	O
,	O
524	O
patients	O
and	O
1	O
,	O
436	O
controls	O
)	O
and	O
found	O
nominal	O
P	O
-	O
values	O
both	O
in	O
the	O
PLCXD3	B-GP
and	O
PLEKHA5	B-GP
loci	O
with	O
the	O
WTCCC	O
sample	O
.	O

In	O
addition	O
,	O
we	O
identified	O
in	O
the	O
French	O
cohort	O
one	O
affected	O
individual	O
with	O
a	O
deletion	O
at	O
the	O
PLCXD3	B-GP
locus	O
and	O
another	O
one	O
carrying	O
a	O
missense	O
variation	O
in	O
PLCXD3	B-GP
(	O
p	O
.	O
R93H	O
),	O
both	O
supporting	O
a	O
role	O
of	O
the	O
phosphatidylinositol	O
pathway	O
in	O
early	O
-	O
onset	O
bipolar	B-DS
disorder	I-DS
vulnerability	O
.	O

Although	O
the	O
current	O
nominally	O
significant	O
findings	O
should	O
be	O
interpreted	O
with	O
caution	O
and	O
need	O
replication	O
in	O
independent	O
cohorts	O
,	O
this	O
study	O
supports	O
the	O
strategy	O
to	O
combine	O
genetic	O
approaches	O
to	O
determine	O
the	O
molecular	O
mechanisms	O
underlying	O
bipolar	B-DS
disorder	I-DS
.	O

Introduction	O

Numerous	O
genome	O
-	O
wide	O
association	O
(	O
GWA	O
)	O
studies	O
have	O
recently	O
been	O
performed	O
on	O
bipolar	B-DS
disorder	I-DS
(	O
BD	B-DS
),	O
but	O
few	O
signals	O
were	O
replicated	O
and	O
meta	O
-	O
analyses	O
identified	O
only	O
a	O
couple	O
of	O
associated	O
genes	O
,	O
such	O
as	O
CACNA1C	B-GP
,	O
ODZ4	B-GP
and	O
NCAN	B-GP
,	O
with	O
a	O
small	O
effect	O
size	O
[	O
1	O
]–[	O
4	O
].	O

Although	O
convergent	O
evidences	O
argue	O
in	O
favour	O
of	O
a	O
role	O
for	O
these	O
genes	O
in	O
vulnerability	O
to	O
BD	B-DS
[	O
5	O
]–[	O
9	O
],	O
more	O
extensive	O
studies	O
suggest	O
it	O
might	O
be	O
involved	O
in	O
other	O
psychiatric	B-DS
disorders	I-DS
[	O
3	O
],	O
[	O
10	O
],	O
[	O
11	O
].	O

The	O
difficulty	O
to	O
identify	O
susceptibility	O
genes	O
specific	O
to	O
BD	B-DS
could	O
be	O
due	O
to	O
the	O
ethnic	O
heterogeneity	O
,	O
as	O
a	O
consequence	O
of	O
the	O
huge	O
number	O
of	O
patients	O
and	O
controls	O
required	O
to	O
get	O
genome	O
-	O
wide	O
significant	O
signals	O
,	O
or	O
to	O
the	O
clinical	O
and	O
a	O
genetic	O
heterogeneity	O
of	O
the	O
DSM	O
-	O
IV	O
“	O
bipolar	B-DS
disorder	I-DS
”	O
entity	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
focused	O
on	O
patients	O
with	O
BD	B-DS
selected	O
with	O
an	O
early	O
age	O
at	O
onset	O
,	O
a	O
clinical	O
characteristic	O
known	O
to	O
identify	O
a	O
subgroup	O
of	O
patients	O
with	O
a	O
higher	O
morbid	O
risk	O
for	O
BD	B-DS
in	O
relatives	O
[	O
12	O
]–[	O
17	O
].	O

We	O
then	O
compared	O
these	O
data	O
to	O
those	O
observed	O
in	O
two	O
previously	O
published	O
GWA	O
studies	O
of	O
BD	B-DS
,	O
conducted	O
by	O
the	O
Wellcome	O
Trust	O
Case	O
Control	O
Consortium	O
(	O
WTCCC	O
)	O
[	O
18	O
]	O
and	O
the	O
Genetic	O
Association	O
Information	O
Network	O
Bipolar	O
Sample	O
(	O
GAIN	O
-	O
BP	O
)	O
[	O
19	O
].	O

Finally	O
,	O
we	O
screened	O
our	O
regions	O
of	O
interest	O
for	O
rare	O
variants	O
,	O
suspected	O
to	O
have	O
a	O
larger	O
effect	O
size	O
,	O
and	O
suggested	O
the	O
importance	O
of	O
combined	O
approaches	O
in	O
the	O
identification	O
of	O
vulnerability	O
genes	O
to	O
BD	B-DS
.	O

Materials	O
and	O
Methods	O

Ethics	O
Statement	O

Protocols	O
and	O
procedures	O
were	O
approved	O
by	O
the	O
research	O
ethics	O
board	O
of	O
the	O
Pitié	O
-	O
Salpêtrière	O
Hospital	O
in	O
Paris	O
for	O
the	O
French	O
sample	O
and	O
the	O
ethics	O
committees	O
of	O
the	O
Faculties	O
of	O
Medicine	O
at	O
the	O
Universities	O
of	O
Bonn	O
and	O
Mannheim	O
/	O
Heidelberg	O
for	O
the	O
German	O
sample	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
subjects	O
prior	O
to	O
study	O
participation	O
.	O

Sample	O

French	O
sample	O

Two	O
hundred	O
and	O
twenty	O
patients	O
of	O
French	O
descent	O
with	O
at	O
least	O
three	O
grandparents	O
from	O
mainland	O
France	O
were	O
collected	O
through	O
a	O
French	O
national	O
network	O
for	O
mental	O
health	O
(	O
Fondation	O
FondaMental	O
)	O
in	O
three	O
university	O
-	O
affiliated	O
psychiatry	O
departments	O
(	O
Paris	O
-	O
Créteil	O
,	O
Bordeaux	O
and	O
Nancy	O
)	O
as	O
previously	O
described	O
[	O
12	O
].	O

All	O
patients	O
met	O
DSM	O
-	O
IV	O
criteria	O
[	O
20	O
]	O
for	O
BD	B-DS
type	I-DS
I	I-DS
(	O
N	O
=	O
172	O
),	O
type	O
II	O
(	O
N	O
=	O
46	O
)	O
or	O
BD	B-DS
not	O
otherwise	O
specified	O
(	O
N	O
=	O
2	O
)	O
before	O
the	O
age	O
of	O
22	O
.	O

The	O
age	O
at	O
onset	O
was	O
defined	O
by	O
the	O
first	O
mood	O
episode	O
(	O
depressive	O
,	O
manic	B-DS
or	O
hypomanic	O
)	O
and	O
was	O
retrospectively	O
assessed	O
using	O
medical	O
case	O
notes	O
and	O
information	O
obtained	O
with	O
the	O
Diagnostic	O
Interview	O
for	O
Genetic	O
Studies	O
(	O
DIGS	O
)	O
[	O
21	O
].	O

The	O
threshold	O
of	O
22	O
was	O
chosen	O
on	O
the	O
basis	O
of	O
previous	O
admixture	O
analyses	O
[	O
16	O
],	O
[	O
22	O
]–[	O
25	O
].	O

German	O
sample	O

One	O
hundred	O
and	O
sixty	O
-	O
seven	O
German	O
patients	O
were	O
recruited	O
from	O
consecutive	O
admissions	O
to	O
the	O
psychiatric	O
inpatient	O
units	O
of	O
the	O
Central	O
Institute	O
of	O
Mental	O
Health	O
in	O
Mannheim	O
and	O
the	O
Department	O
of	O
Psychiatry	O
and	O
Psychotherapy	O
of	O
the	O
University	O
of	O
Bonn	O
(	O
BOMA	O
bipolar	O
study	O
).	O

These	O
patients	O
received	O
a	O
lifetime	O
diagnosis	O
of	O
BD	B-DS
type	I-DS
I	I-DS
based	O
on	O
DSM	O
-	O
IV	O
criteria	O
and	O
had	O
an	O
age	O
at	O
onset	O
lower	O
than	O
22	O
.	O

Control	O
population	O

Genotyping	O
data	O
from	O
1	O
,	O
823	O
French	O
controls	O
and	O
629	O
German	O
controls	O
were	O
provided	O
by	O
the	O
Centre	O
National	O
de	O
Génotypage	O
(	O
CNG	O
,	O
Evry	O
,	O
France	O
).	O

These	O
samples	O
were	O
previously	O
collected	O
and	O
were	O
not	O
screened	O
for	O
psychiatric	B-DS
disorders	I-DS
.	O

They	O
have	O
been	O
genotyped	O
for	O
association	O
and	O
population	O
studies	O
as	O
described	O
elsewhere	O
[	O
26	O
]	O
and	O
permission	O
to	O
use	O
them	O
were	O
obtained	O
from	O
the	O
original	O
investigators	O
.	O

DNA	O
from	O
380	O
additional	O
German	O
controls	O
were	O
collected	O
in	O
the	O
above	O
mentioned	O
German	O
hospitals	O
.	O

An	O
additional	O
sample	O
of	O
293	O
unaffected	O
French	O
controls	O
screened	O
for	O
personal	O
history	O
of	O
psychiatric	B-DS
disorders	I-DS
using	O
the	O
DIGS	O
has	O
been	O
screened	O
for	O
mutation	O
in	O
the	O
PLCXD3	B-GP
exon	O
2	O
,	O
in	O
order	O
to	O
determine	O
the	O
specificity	O
of	O
the	O
p	O
.	O
R93H	O
mutation	O
.	O

DNA	O
extraction	O
and	O
genotyping	O

DNA	O
was	O
isolated	O
from	O
lymphocytes	O
either	O
directly	O
from	O
venous	O
blood	O
sample	O
or	O
after	O
transformation	O
by	O
Epstein	B-OG
Barr	I-OG
virus	I-OG
.	O

Isolation	O
was	O
performed	O
by	O
salting	O
-	O
out	O
with	O
saturated	O
sodium	O
chloride	O
solution	O
[	O
27	O
].	O

French	O
and	O
German	O
cases	O
were	O
genotyped	O
at	O
the	O
CNG	O
,	O
using	O
HumanHap550	O
or	O
Human	O
610	O
-	O
Quad	O
BeadArrays	O
and	O
the	O
Infinium	O
II	O
assay	O
(	O
Illumina	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
).	O

Control	O
samples	O
were	O
genotyped	O
on	O
HumanHap300	O
(	O
N	O
=	O
2	O
,	O
503	O
)	O
or	O
on	O
HumanHap550	O
BeadArrays	O
(	O
N	O
=	O
380	O
).	O

In	O
order	O
to	O
determine	O
whether	O
the	O
use	O
of	O
multiple	O
arrays	O
might	O
result	O
in	O
a	O
population	O
stratification	O
,	O
we	O
performed	O
a	O
multidimensional	O
scaling	O
analysis	O
based	O
on	O
pairwise	O
identity	O
-	O
by	O
-	O
state	O
distance	O
between	O
pairs	O
of	O
individuals	O
.	O

The	O
good	O
clustering	O
of	O
all	O
individuals	O
showed	O
that	O
there	O
was	O
no	O
stratification	O
due	O
to	O
the	O
use	O
of	O
multiple	O
arrays	O
(	O
Figure	O
S1	O
in	O
File	O
S1	O
).	O

Quality	O
control	O
criteria	O

All	O
samples	O
were	O
passed	O
through	O
the	O
standard	O
quality	O
-	O
control	O
procedures	O
followed	O
at	O
the	O
CNG	O
for	O
GWA	O
studies	O
,	O
as	O
described	O
elsewhere	O
[	O
26	O
].	O

For	O
the	O
French	O
population	O
,	O
the	O
quality	O
control	O
was	O
performed	O
using	O
the	O
PLINK	O
toolset	O
[	O
28	O
]	O
on	O
a	O
total	O
of	O
317	O
,	O
131	O
commons	O
SNPs	O
genotyped	O
in	O
2	O
,	O
043	O
DNA	O
samples	O
(	O
Table	O
S1	O
in	O
File	O
S1	O
).	O

We	O
removed	O
monomorphic	O
SNPs	O
,	O
as	O
those	O
with	O
a	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
lower	O
than	O
0	O
.	O
01	O
and	O
SNPs	O
with	O
a	O
call	O
rate	O
lower	O
than	O
0	O
.	O
97	O
.	O

We	O
performed	O
a	O
missing	O
chi	O
-	O
square	O
test	O
that	O
compares	O
,	O
for	O
each	O
SNP	O
,	O
missingness	O
between	O
cases	O
and	O
controls	O
and	O
excluded	O
SNPs	O
with	O
P	O
<	O
10	O
−	O
3	O
.	O

Then	O
,	O
we	O
removed	O
SNPs	O
that	O
did	O
not	O
show	O
Hardy	O
-	O
Weinberg	O
proportions	O
in	O
controls	O
,	O
using	O
a	O
significant	O
threshold	O
at	O
P	O
<	O
10	O
−	O
3	O
.	O

In	O
parallel	O
,	O
we	O
removed	O
male	O
samples	O
with	O
more	O
than	O
0	O
.	O
5	O
%	O
or	O
female	O
samples	O
with	O
less	O
than	O
20	O
%	O
heterozygous	O
markers	O
on	O
the	O
X	O
chromosome	O
and	O
individuals	O
with	O
a	O
call	O
rate	O
lower	O
than	O
0	O
.	O
97	O
.	O

We	O
estimated	O
the	O
average	O
genome	O
-	O
wide	O
identity	O
-	O
by	O
-	O
state	O
(	O
IBS	O
)	O
sharing	O
between	O
individuals	O
and	O
analysed	O
the	O
clustering	O
using	O
a	O
multidimensional	O
scaling	O
(	O
MDS	O
)	O
plot	O
.	O

Hence	O
,	O
we	O
excluded	O
15	O
individuals	O
(	O
3	O
cases	O
and	O
12	O
controls	O
)	O
with	O
a	O
low	O
level	O
of	O
identity	O
.	O

After	O
pruning	O
,	O
the	O
final	O
data	O
set	O
consisted	O
in	O
261	O
,	O
525	O
SNPs	O
genotyped	O
in	O
1	O
,	O
930	O
individuals	O
(	O
211	O
cases	O
and	O
1	O
,	O
719	O
controls	O
)	O
that	O
were	O
used	O
for	O
association	O
study	O
.	O

Identical	O
quality	O
control	O
criteria	O
were	O
used	O
for	O
the	O
replication	O
sample	O
from	O
Germany	O
(	O
Table	O
S1	O
in	O
File	O
S1	O
)	O
and	O
MDS	O
plot	O
showed	O
6	O
controls	O
to	O
be	O
removed	O
.	O

This	O
led	O
to	O
a	O
final	O
data	O
set	O
of	O
288	O
,	O
167	O
SNPs	O
and	O
1	O
,	O
157	O
individuals	O
(	O
159	O
patients	O
and	O
998	O
controls	O
).	O

Association	O
analysis	O

Basic	O
case	O
/	O
control	O
association	O
analyses	O
were	O
performed	O
using	O
the	O
PLINK	O
software	O
v1	O
.	O
07	O
[	O
28	O
].	O

A	O
haplotype	O
analysis	O
was	O
performed	O
on	O
the	O
two	O
most	O
associated	O
regions	O
using	O
sliding	O
windows	O
of	O
two	O
to	O
five	O
SNPs	O
shifting	O
by	O
one	O
SNP	O
at	O
a	O
time	O
.	O

We	O
tested	O
for	O
case	O
/	O
control	O
haplotype	O
-	O
based	O
association	O
using	O
a	O
chi	O
-	O
square	O
test	O
with	O
one	O
degree	O
of	O
freedom	O
.	O

Only	O
window	O
with	O
best	O
P	O
-	O
values	O
are	O
reported	O
for	O
each	O
region	O
.	O

Imputation	O
data	O
were	O
based	O
on	O
the	O
3	O
,	O
967	O
,	O
651	O
SNPs	O
genotyped	O
in	O
90	O
subjects	O
of	O
the	O
CEU	O
population	O
of	O
the	O
HapMap	O
project	O
(	O
http	O
://	O
www	O
.	O
hapmap	O
.	O
org	O
).	O

Imputation	O
was	O
performed	O
using	O
PLINK	O
and	O
consisted	O
in	O
estimating	O
the	O
allele	O
frequencies	O
of	O
an	O
ungenotyped	O
SNP	O
based	O
on	O
its	O
surrounding	O
haplotypic	O
background	O
.	O

Genotyping	O
data	O
from	O
the	O
WTCCC	O
[	O
18	O
]	O
and	O
the	O
GAIN	O
-	O
TGen	O
collection	O
[	O
19	O
]	O
were	O
provided	O
for	O
BD	B-DS
patients	O
with	O
an	O
age	O
at	O
onset	O
lower	O
than	O
22	O
and	O
for	O
controls	O
.	O

In	O
the	O
WTCCC	O
,	O
BD	B-DS
was	O
defined	O
according	O
to	O
Research	O
Diagnostic	O
Criteria	O
[	O
29	O
]	O
and	O
included	O
BD	B-DS
type	I-DS
I	I-DS
,	O
type	O
II	O
,	O
schizoaffective	B-DS
disorders	I-DS
and	O
manic	B-DS
disorders	I-DS
.	O

The	O
WTCCC	O
sample	O
was	O
genotyped	O
on	O
Affymetrix	O
500K	O
array	O
,	O
containing	O
only	O
few	O
SNPs	O
in	O
common	O
with	O
the	O
Illumina	O
arrays	O
used	O
in	O
other	O
samples	O
.	O

Thus	O
,	O
the	O
genotype	O
correlation	O
data	O
were	O
obtained	O
for	O
SNPs	O
within	O
a	O
1	O
Mbp	O
window	O
,	O
based	O
on	O
individuals	O
and	O
SNPs	O
in	O
the	O
CEU	O
HapMap	O
filtered	O
set	O
(	O
http	O
://	O
www	O
.	O
hapmap	O
.	O
org	O
)	O
and	O
the	O
2	O
,	O
938	O
WTCCC	O
control	O
sample	O
combined	O
[	O
18	O
].	O

An	O
association	O
test	O
between	O
764	O
early	O
-	O
onset	O
patients	O
and	O
2	O
,	O
938	O
controls	O
was	O
performed	O
,	O
using	O
SNPs	O
with	O
a	O
genotyped	O
correlation	O
higher	O
than	O
0	O
.	O
2	O
with	O
associated	O
SNPs	O
at	O
P	O
<	O
5	O
×	O
10	O
−	O
5	O
identified	O
through	O
the	O
meta	O
-	O
analysis	O
.	O

All	O
patients	O
from	O
the	O
GAIN	O
-	O
TGen	O
cohort	O
met	O
DSM	O
-	O
IV	O
criteria	O
for	O
BD	B-DS
type	I-DS
I	I-DS
.	O

Imputed	O
data	O
from	O
the	O
GAIN	O
-	O
TGen	O
bipolar	O
case	O
-	O
control	O
sample	O
[	O
30	O
]	O
were	O
obtained	O
,	O
using	O
the	O
MACH	O
software	O
with	O
phased	O
haplotypes	O
from	O
the	O
60	O
HapMap	O
-	O
CEU	O
founders	O
(	O
release	O
22	O
).	O

Allele	O
frequencies	O
of	O
15	O
SNPs	O
out	O
of	O
the	O
16	O
associated	O
SNPs	O
at	O
P	O
<	O
5	O
×	O
10	O
−	O
5	O
,	O
were	O
compared	O
between	O
1	O
,	O
524	O
patients	O
with	O
an	O
early	O
age	O
at	O
onset	O
and	O
1	O
,	O
436	O
controls	O
.	O

A	O
flow	O
chart	O
summarizing	O
all	O
steps	O
of	O
the	O
genetic	O
analysis	O
is	O
shown	O
on	O
the	O
Figure	O
S2	O
in	O
File	O
S1	O
.	O

Detection	O
of	O
copy	O
number	O
variations	O

Copy	O
number	O
variations	O
were	O
detected	O
by	O
fluorescence	O
level	O
comparison	O
through	O
the	O
chromosome	O
,	O
using	O
the	O
SnipPeep	O
software	O
(	O
R	O
.	O

Toro	O
,	O
Pasteur	O
Institute	O
,	O
France	O
).	O

The	O
deletion	O
in	O
PLCXD3	B-GP
was	O
confirmed	O
by	O
quantitative	O
PCR	O
analysis	O
using	O
one	O
internal	O
and	O
two	O
external	O
couples	O
of	O
primers	O
and	O
Mesa	O
Green	O
qPCR	O
master	O
mix	O
plus	O
(	O
Eurogentec	O
,	O
Liege	O
,	O
Belgium	O
).	O

PCR	O
were	O
performed	O
and	O
run	O
in	O
a	O
Mastercycler	O
ep	O
realplex2S	O
(	O
Eppendorf	O
,	O
Hamburg	O
,	O
Germany	O
)	O
for	O
the	O
deleted	O
patient	O
and	O
two	O
unaffected	O
controls	O
,	O
known	O
to	O
have	O
no	O
deletion	O
in	O
the	O
regions	O
under	O
study	O
.	O

Each	O
real	O
-	O
time	O
PCR	O
was	O
performed	O
in	O
triplicate	O
and	O
assessed	O
by	O
comparing	O
Ct	O
at	O
a	O
determined	O
threshold	O
between	O
the	O
three	O
amplicons	O
and	O
the	O
three	O
individuals	O
.	O

Mutation	O
screening	O
in	O
PLCXD3	B-GP

The	O
PLCXD3	B-GP
coding	O
regions	O
were	O
amplified	O
for	O
334	O
French	O
subjects	O
with	O
BD	B-DS
,	O
sequenced	O
by	O
the	O
Sanger	O
'	O
s	O
method	O
using	O
the	O
BigDye	O
terminator	O
v3	O
.	O
1	O
cycle	O
sequencing	O
kit	O
(	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
,	O
U	O
.	O
S	O
.	O
A	O
.)	O
and	O
run	O
on	O
a	O
16	O
-	O
Capillary	O
ABI	O
PRISM	O
3130xl	O
genetic	O
analyzer	O
.	O

The	O
PLCXD3	B-GP
exon	O
2	O
was	O
sequenced	O
for	O
293	O
unaffected	O
French	O
controls	O
.	O

All	O
primers	O
used	O
for	O
PCR	O
amplifications	O
and	O
sequence	O
analyses	O
are	O
available	O
on	O
request	O
.	O

Results	O

Analysis	O
of	O
a	O
French	O
cohort	O

We	O
carried	O
out	O
an	O
association	O
study	O
on	O
211	O
patients	O
with	O
early	O
-	O
onset	O
BD	B-DS
of	O
French	O
origin	O
and	O
1	O
,	O
719	O
matched	O
controls	O
,	O
who	O
have	O
been	O
genotyped	O
on	O
an	O
Illumina	O
platform	O
with	O
261	O
,	O
525	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
passing	O
quality	O
control	O
.	O

The	O
estimation	O
of	O
an	O
inflation	O
factor	O
[	O
31	O
]	O
showed	O
a	O
good	O
genetic	O
homogeneity	O
in	O
our	O
sample	O
(	O
λ	O
=	O
1	O
.	O
03	O
),	O
suggesting	O
that	O
no	O
correction	O
for	O
genomic	O
control	O
was	O
needed	O
.	O

According	O
to	O
the	O
genome	O
-	O
wide	O
significance	O
threshold	O
of	O
P	O
=	O
5	O
×	O
10	O
−	O
8	O
,	O
no	O
significant	O
difference	O
in	O
allele	O
frequencies	O
was	O
observed	O
in	O
our	O
sample	O
,	O
but	O
17	O
SNPs	O
showed	O
a	O
nominal	O
P	O
<	O
5	O
×	O
10	O
−	O
5	O
(	O
Table	O
S2	O
in	O
File	O
S1	O
),	O
suggesting	O
these	O
loci	O
may	O
be	O
associated	O
with	O
vulnerability	O
to	O
early	O
-	O
onset	O
forms	O
of	O
BD	B-DS
.	O

Interestingly	O
,	O
the	O
lowest	O
P	O
-	O
value	O
(	O
rs10096683	O
,	O
P	O
=	O
4	O
.	O
11	O
×	O
10	O
−	O
6	O
,	O
OR	O
=	O
2	O
.	O
26	O
),	O
was	O
observed	O
for	O
a	O
SNP	O
located	O
on	O
chromosome	O
8p22	O
,	O
a	O
region	O
that	O
has	O
previously	O
been	O
associated	O
with	O
schizophrenia	B-DS
[	O
32	O
]–[	O
35	O
]	O
and	O
suicide	O
behaviour	O
in	O
patients	O
with	O
recurrent	B-DS
major	I-DS
depression	I-DS
[	O
36	O
].	O

Replication	O
on	O
a	O
German	O
cohort	O

Next	O
,	O
we	O
selected	O
14	O
,	O
037	O
SNPs	O
with	O
a	O
P	O
<	O
0	O
.	O
05	O
to	O
perform	O
a	O
replication	O
study	O
on	O
an	O
independent	O
sample	O
of	O
159	O
German	O
subjects	O
with	O
an	O
early	O
-	O
onset	O
BD	B-DS
and	O
998	O
matched	O
controls	O
(	O
Table	O
S1	O
in	O
File	O
S1	O
).	O

Again	O
,	O
a	O
good	O
genetic	O
homogeneity	O
(	O
λ	O
=	O
1	O
.	O
04	O
)	O
was	O
observed	O
after	O
quality	O
control	O
for	O
this	O
sample	O
.	O

Out	O
of	O
the	O
14	O
,	O
037	O
SNPs	O
previously	O
selected	O
,	O
13	O
,	O
734	O
were	O
genotyped	O
in	O
the	O
German	O
sample	O
,	O
and	O
739	O
showed	O
a	O
P	O
<	O
0	O
.	O
05	O
,	O
showing	O
a	O
significant	O
over	O
-	O
representation	O
(	O
P	O
<	O
0	O
.	O
03	O
)	O
of	O
nominally	O
significant	O
P	O
-	O
values	O
.	O

The	O
most	O
associated	O
SNP	O
in	O
the	O
German	O
sample	O
was	O
located	O
on	O
chromosome	O
12	O
upstream	O
to	O
the	O
PLEKHA5	B-GP
gene	O
(	O
rs2970836	O
,	O
P	O
=	O
5	O
.	O
3	O
×	O
10	O
−	O
6	O
,	O
OR	O
=	O
1	O
.	O
76	O
).	O

Meta	O
-	O
analysis	O
on	O
the	O
French	O
and	O
the	O
German	O
cohorts	O

We	O
subsequently	O
performed	O
a	O
meta	O
-	O
analysis	O
,	O
combining	O
data	O
from	O
the	O
French	O
and	O
the	O
German	O
cohorts	O
,	O
yielding	O
a	O
sample	O
of	O
370	O
patients	O
with	O
early	O
-	O
onset	O
BD	B-DS
and	O
2	O
,	O
717	O
controls	O
.	O

Again	O
,	O
no	O
locus	O
reaches	O
the	O
genome	O
-	O
wide	O
significant	O
threshold	O
.	O

The	O
largest	O
difference	O
in	O
allele	O
frequencies	O
between	O
cases	O
and	O
controls	O
was	O
observed	O
for	O
chromosome	O
12	O
(	O
rs2961365	O
,	O
P	O
meta	O
=	O
1	O
.	O
6	O
×	O
10	O
−	O
6	O
,	O
ORmeta	O
=	O
1	O
.	O
57	O
)	O
with	O
no	O
evidence	O
of	O
heterogeneity	O
between	O
the	O
two	O
cohorts	O
(	O
Q	O
=	O
0	O
.	O
94	O
,	O
1	O
degree	O
of	O
freedom	O
,	O
I2	O
=	O
0	O
).	O

In	O
this	O
region	O
,	O
5	O
SNPs	O
showed	O
a	O
difference	O
in	O
allele	O
frequencies	O
at	O
P	O
<	O
5	O
×	O
10	O
−	O
5	O
in	O
355	O
Kbp	O
(	O
Figure	O
1	O
,	O
Table	O
1	O
).	O

These	O
SNPs	O
span	O
two	O
genes	O
,	O
PLEKHA5	B-GP
and	O
AEBP2	B-GP
.	O

The	O
second	O
strongest	O
association	O
with	O
no	O
heterogeneity	O
(	O
Q	O
=	O
0	O
.	O
59	O
,	O
1	O
degree	O
of	O
freedom	O
,	O
I2	O
=	O
0	O
)	O
was	O
observed	O
for	O
chromosome	O
5p13	O
(	O
rs10512793	O
,	O
P	O
meta	O
=	O
2	O
.	O
7	O
×	O
10	O
−	O
6	O
,	O
ORmeta	O
=	O
1	O
.	O
61	O
),	O
in	O
which	O
two	O
SNPs	O
,	O
spaced	O
by	O
196	O
Kbp	O
,	O
showed	O
a	O
difference	O
in	O
allele	O
frequencies	O
at	O
P	O
<	O
5	O
×	O
10	O
−	O
5	O
(	O
Figure	O
1	O
,	O
Table	O
1	O
).	O

These	O
two	O
SNPs	O
were	O
located	O
in	O
the	O
OXCT1	B-GP
gene	O
,	O
and	O
upstream	O
to	O
PLCXD3	B-GP
.	O

In	O
order	O
to	O
further	O
explore	O
the	O
associated	O
peak	O
in	O
these	O
two	O
regions	O
,	O
we	O
used	O
a	O
three	O
-	O
SNP	O
sliding	O
window	O
and	O
performed	O
a	O
haplotype	O
analysis	O
.	O

Whereas	O
no	O
further	O
significant	O
difference	O
,	O
as	O
compared	O
to	O
single	O
SNP	O
analysis	O
,	O
was	O
observed	O
on	O
chromosome	O
12p12	O
,	O
a	O
more	O
significant	O
difference	O
between	O
patients	O
and	O
controls	O
was	O
observed	O
on	O
chromosome	O
5p13	O
for	O
the	O
combination	O
of	O
rs624097	O
-	O
rs316762	O
-	O
rs10512793	O
,	O
for	O
which	O
an	O
overall	O
P	O
meta	O
=	O
2	O
.	O
6	O
×	O
10	O
−	O
7	O
was	O
observed	O
(	O
Figure	O
1	O
).	O

Genome	O
-	O
wide	O
association	O
results	O
and	O
detailed	O
peak	O
association	O
regions	O
.	O

(	O
A	O
)	O
Manhattan	O
plot	O
of	O
the	O
meta	O
-	O
analysis	O
performed	O
on	O
early	O
-	O
onset	O
bipolar	O
patients	O
and	O
controls	O
from	O
France	O
and	O
Germany	O
.	O

Physical	O
position	O
is	O
shown	O
along	O
the	O
x	O
axis	O
and	O
–	O
log10	O
(	O
P	O
-	O
value	O
)	O
is	O
shown	O
along	O
the	O
y	O
axis	O
.	O

(	O
B	O
)	O
Detail	O
of	O
the	O
two	O
most	O
associated	O
regions	O
on	O
chromosomes	O
5p13	O
and	O
12p12	O
.	O

Allele	O
frequency	O
differences	O
are	O
represented	O
by	O
–	O
log10	O
(	O
P	O
-	O
values	O
)	O
for	O
the	O
French	O
(	O
open	O
grey	O
circles	O
),	O
the	O
German	O
(	O
open	O
grey	O
squares	O
)	O
and	O
the	O
meta	O
-	O
(	O
open	O
red	O
diamonds	O
)	O
analyses	O
.	O

Grey	O
crosses	O
represent	O
–	O
log10	O
(	O
P	O
-	O
value	O
)	O
for	O
imputed	O
ungenotyped	O
SNPs	O
.	O

The	O
most	O
associated	O
SNP	O
for	O
each	O
region	O
is	O
shown	O
with	O
orange	O
circle	O
.	O

On	O
chromosome	O
12p12	O
,	O
the	O
lowest	O
P	O
-	O
value	O
(	O
P	O
=	O
2	O
.	O
1	O
×	O
10	O
−	O
7	O
)	O
was	O
observed	O
for	O
an	O
imputed	O
SNP	O
(	O
rs10743315	O
).	O

On	O
chromosome	O
5p13	O
,	O
the	O
lowest	O
P	O
-	O
value	O
(	O
P	O
=	O
2	O
.	O
6	O
×	O
10	O
−	O
7	O
)	O
was	O
observed	O
for	O
a	O
three	O
-	O
SNPs	O
window	O
haplotype	O
(	O
light	O
blue	O
line	O
)	O
located	O
downstream	O
to	O
OXCT1	B-GP
and	O
upstream	O
to	O
PLCXD3	B-GP
(	O
rs624097	O
-	O
rs316762	O
-	O
rs10512793	O
).	O

The	O
genome	O
-	O
wide	O
significant	O
threshold	O
(	O
P	O
=	O
5	O
×	O
10	O
−	O
8	O
)	O
is	O
indicated	O
by	O
the	O
blue	O
dash	O
line	O
and	O
the	O
dot	O
black	O
line	O
shows	O
a	O
threshold	O
at	O
P	O
=	O
5	O
×	O
10	O
−	O
5	O
.	O

The	O
largest	O
differences	O
in	O
allele	O
frequencies	O
are	O
represented	O
with	O
filled	O
diamonds	O
.	O

Gene	O
position	O
and	O
annotation	O
(	O
http	O
://	O
genome	O
.	O
ucsc	O
.	O
edu	O
/)	O
are	O
symbolised	O
by	O
green	O
arrows	O
.	O

Linkage	O
disequilibrium	O
(	O
r2	O
)	O
estimated	O
according	O
to	O
HapMap	O
CEU	O
population	O
SNPs	O
(	O
release	O
3	O
)	O
is	O
symbolised	O
in	O
the	O
bottom	O
part	O
of	O
each	O
figure	O
.	O

Darker	O
red	O
indicates	O
higher	O
values	O
.	O

Regions	O
associated	O
at	O
P	O
<	O
5	O
×	O
10	O
−	O
5	O
with	O
early	O
-	O
onset	O
BD	B-DS
in	O
meta	O
-	O
analysis	O
.	O

French	O
sample	O

German	O
sample	O

Meta	O
-	O
analysis	O

CHR	O

SNP	O

Positiona	O
(	O
bp	O
)	O

Allele	O

Allele	O
frequency	O
in	O
early	O
-	O
onset	O
BD	B-DS
patients	O

Allele	O
frequency	O
in	O
controls	O

P	O

OR	O

Allele	O
frequency	O
in	O
early	O
-	O
onset	O
BD	B-DS
patients	O

Allele	O
frequency	O
in	O
controls	O

P	O

OR	O

P	O
meta	O

ORmeta	O

Q	O

I2	O

12	O

rs2961365	O

19	O
,	O
469	O
,	O
374	O

T	O

0	O
,	O
23	O

0	O
,	O
16	O

1	O
,	O
88	O
×	O
10	O
−	O
04	O

1	O
,	O
58	O

0	O
.	O
23	O

0	O
.	O
16	O

2	O
.	O
12	O
×	O
10	O
−	O
03	O

1	O
.	O
56	O

1	O
.	O
58	O
×	O
10	O
−	O
6	O

1	O
.	O
57	O

0	O
.	O
94	O

0	O

12	O

rs3752823	O

19	O
,	O
419	O
,	O
905	O

A	O

0	O
,	O
15	O

0	O
,	O
10	O

2	O
,	O
03	O
×	O
10	O
−	O
03	O

1	O
,	O
58	O

0	O
.	O
16	O

0	O
.	O
09	O

1	O
.	O
70	O
×	O
10	O
−	O
04	O

1	O
.	O
89	O

2	O
.	O
09	O
×	O
10	O
−	O
6	O

1	O
.	O
71	O

0	O
.	O
43	O

0	O

5	O

rs10512793	O

41	O
,	O
787	O
,	O
459	O

C	O

0	O
,	O
19	O

0	O
,	O
13	O

1	O
,	O
24	O
×	O
10	O
−	O
03	O

1	O
,	O
54	O

0	O
.	O
20	O

0	O
.	O
13	O

4	O
.	O
64	O
×	O
10	O
−	O
04	O

1	O
.	O
72	O

2	O
.	O
68	O
×	O
10	O
−	O
6	O

1	O
.	O
61	O

0	O
.	O
59	O

0	O

12	O

rs2900433	O

19	O
,	O
588	O
,	O
898	O

T	O

0	O
,	O
23	O

0	O
,	O
16	O

4	O
,	O
13	O
×	O
10	O
−	O
04	O

1	O
,	O
55	O

0	O
.	O
23	O

0	O
.	O
16	O

2	O
.	O
01	O
×	O
10	O
−	O
03	O

1	O
.	O
57	O

3	O
.	O
13	O
×	O
10	O
−	O
6	O

1	O
.	O
56	O

0	O
.	O
96	O

0	O

12	O

rs7305762	O

19	O
,	O
535	O
,	O
793	O

G	O

0	O
,	O
23	O

0	O
,	O
16	O

2	O
,	O
46	O
×	O
10	O
−	O
04	O

1	O
,	O
57	O

0	O
.	O
23	O

0	O
.	O
16	O

3	O
.	O
53	O
×	O
10	O
−	O
03	O

1	O
.	O
53	O

3	O
.	O
26	O
×	O
10	O
−	O
6	O

1	O
.	O
55	O

0	O
.	O
89	O

0	O

4	O

rs12500759	O

7	O
,	O
760	O
,	O
780	O

T	O

0	O
,	O
21	O

0	O
,	O
29	O

7	O
,	O
54	O
×	O
10	O
−	O
04	O

0	O
,	O
66	O

0	O
.	O
23	O

0	O
.	O
32	O

2	O
.	O
76	O
×	O
10	O
−	O
03	O

0	O
.	O
66	O

7	O
.	O
40	O
×	O
10	O
−	O
6	O

0	O
.	O
66	O

1	O
.	O
00	O

0	O

X	O

rs952076	O

13	O
,	O
856	O
,	O
877	O

T	O

0	O
,	O
20	O

0	O
,	O
28	O

2	O
,	O
61	O
×	O
10	O
−	O
03	O

0	O
,	O
65	O

0	O
.	O
19	O

0	O
.	O
29	O

5	O
.	O
94	O
×	O
10	O
−	O
04	O

0	O
.	O
56	O

7	O
.	O
48	O
×	O
10	O
−	O
6	O

0	O
.	O
61	O

0	O
.	O
51	O

0	O

5	O

rs822135	O

41	O
,	O
590	O
,	O
915	O

A	O

0	O
,	O
25	O

0	O
,	O
33	O

8	O
,	O
12	O
×	O
10	O
−	O
04	O

0	O
,	O
68	O

0	O
.	O
26	O

0	O
.	O
34	O

5	O
.	O
54	O
×	O
10	O
−	O
03	O

0	O
.	O
69	O

1	O
.	O
50	O
×	O
10	O
−	O
5	O

0	O
.	O
68	O

0	O
.	O
94	O

0	O

12	O

rs4764470	O

19	O
,	O
233	O
,	O
420	O

A	O

0	O
,	O
27	O

0	O
,	O
20	O

2	O
,	O
55	O
×	O
10	O
−	O
04	O

1	O
,	O
53	O

0	O
.	O
25	O

0	O
.	O
20	O

1	O
.	O
84	O
×	O
10	O
−	O
02	O

1	O
.	O
39	O

1	O
.	O
73	O
×	O
10	O
−	O
5	O

1	O
.	O
47	O

0	O
.	O
60	O

0	O

2	O

rs7608161	O

9	O
,	O
668	O
,	O
060	O

G	O

0	O
,	O
34	O

0	O
,	O
27	O

2	O
,	O
90	O
×	O
10	O
−	O
03	O

1	O
,	O
38	O

0	O
.	O
33	O

0	O
.	O
25	O

1	O
.	O
68	O
×	O
10	O
−	O
03	O

1	O
.	O
50	O

1	O
.	O
82	O
×	O
10	O
−	O
5	O

1	O
.	O
43	O

0	O
.	O
64	O

0	O

16	O

rs7185187	O

69	O
,	O
315	O
,	O
056	O

T	O

0	O
,	O
11	O

0	O
,	O
06	O

5	O
,	O
99	O
×	O
10	O
−	O
04	O

1	O
,	O
80	O

0	O
.	O
12	O

0	O
.	O
07	O

9	O
.	O
63	O
×	O
10	O
−	O
03	O

1	O
.	O
65	O

2	O
.	O
24	O
×	O
10	O
−	O
5	O

1	O
.	O
73	O

0	O
.	O
74	O

0	O

4	O

rs6857347	O

139	O
,	O
528	O
,	O
195	O

G	O

0	O
,	O
43	O

0	O
,	O
50	O

6	O
,	O
80	O
×	O
10	O
−	O
03	O

0	O
,	O
75	O

0	O
.	O
41	O

0	O
.	O
51	O

7	O
.	O
62	O
×	O
10	O
−	O
04	O

0	O
.	O
66	O

2	O
.	O
40	O
×	O
10	O
−	O
5	O

0	O
.	O
71	O

0	O
.	O
41	O

0	O

3	O

rs13091545	O

52	O
,	O
352	O
,	O
334	O

G	O

0	O
,	O
25	O

0	O
,	O
18	O

1	O
,	O
73	O
×	O
10	O
−	O
04	O

1	O
,	O
57	O

0	O
.	O
20	O

0	O
.	O
16	O

4	O
.	O
64	O
×	O
10	O
−	O
02	O

1	O
.	O
35	O

3	O
.	O
24	O
×	O
10	O
−	O
5	O

1	O
.	O
48	O

0	O
.	O
44	O

0	O

7	O

rs4716990	O

155	O
,	O
616	O
,	O
697	O

G	O

0	O
,	O
37	O

0	O
,	O
29	O

6	O
,	O
12	O
×	O
10	O
−	O
04	O

1	O
,	O
45	O

0	O
.	O
36	O

0	O
.	O
29	O

1	O
.	O
99	O
×	O
10	O
−	O
02	O

1	O
.	O
34	O

4	O
.	O
04	O
×	O
10	O
−	O
5	O

1	O
.	O
40	O

0	O
.	O
66	O

0	O

4	O

rs12505439	O

139	O
,	O
521	O
,	O
194	O

A	O

0	O
,	O
35	O

0	O
,	O
29	O

9	O
,	O
91	O
×	O
10	O
−	O
03	O

1	O
,	O
32	O

0	O
.	O
40	O

0	O
.	O
30	O

1	O
.	O
05	O
×	O
10	O
−	O
03	O

1	O
.	O
50	O

4	O
.	O
48	O
×	O
10	O
−	O
5	O

1	O
.	O
40	O

0	O
.	O
44	O

0	O

9	O

rs3739657	O

85	O
,	O
177	O
,	O
755	O

C	O

0	O
,	O
28	O

0	O
,	O
36	O

2	O
,	O
21	O
×	O
10	O
−	O
03	O

0	O
,	O
71	O

0	O
.	O
31	O

0	O
.	O
39	O

6	O
.	O
87	O
×	O
10	O
−	O
03	O

0	O
.	O
70	O

4	O
.	O
74	O
×	O
10	O
−	O
5	O

0	O
.	O
71	O

0	O
.	O
98	O

0	O

OR	O
,	O
odds	O
ratio	O
;	O
Q	O
,	O
P	O
-	O
value	O
for	O
Cochrane	O
'	O
s	O
Q	O
statistic	O
;	O
I2	O
,	O
heterogeneity	O
index	O
.	O

position	O
from	O
the	O
short	O
arm	O
telomere	O
based	O
on	O
Hg18	O
.	O

Imputation	O
data	O

In	O
order	O
to	O
refine	O
the	O
association	O
signal	O
in	O
these	O
two	O
regions	O
,	O
we	O
imputed	O
data	O
for	O
ungenotyped	O
SNPs	O
in	O
the	O
French	O
and	O
the	O
German	O
cohorts	O
based	O
on	O
the	O
3	O
.	O
9	O
million	O
SNPs	O
genotyped	O
in	O
the	O
CEU	O
population	O
of	O
the	O
HapMap	O
project	O
.	O

The	O
results	O
of	O
the	O
two	O
populations	O
were	O
then	O
combined	O
to	O
perform	O
an	O
association	O
study	O
.	O

After	O
imputation	O
,	O
we	O
observed	O
an	O
increased	O
signal	O
for	O
chromosome	O
12	O
with	O
the	O
lowest	O
estimated	O
P	O
-	O
value	O
for	O
rs10743315	O
(	O
P	O
=	O
2	O
.	O
1	O
×	O
10	O
−	O
7	O
,	O
OR	O
=	O
1	O
.	O
61	O
)	O
located	O
in	O
PLEKHA5	B-GP
(	O
Figure	O
1	O
).	O

On	O
the	O
contrary	O
for	O
chromosome	O
5	O
,	O
the	O
lowest	O
P	O
-	O
value	O
was	O
observed	O
for	O
the	O
genotyped	O
SNP	O
,	O
rs10512793	O
.	O

Replication	O
studies	O
on	O
the	O
WTCCC	O
and	O
the	O
GAIN	O
-	O
TGen	O
cohorts	O

We	O
analysed	O
the	O
top	O
-	O
16	O
SNPs	O
(	O
P	O
<	O
5	O
×	O
10	O
−	O
5	O
)	O
out	O
of	O
the	O
meta	O
-	O
analysis	O
in	O
two	O
additional	O
samples	O
of	O
early	O
-	O
onset	O
bipolar	O
patients	O
,	O
already	O
genotyped	O
on	O
different	O
platforms	O
through	O
the	O
WTCCC	O
and	O
the	O
GAIN	O
and	O
performed	O
a	O
mega	O
-	O
analysis	O
including	O
the	O
four	O
samples	O
(	O
Table	O
S3	O
in	O
File	O
S2	O
).	O

Only	O
4	O
SNPs	O
,	O
genotyped	O
in	O
a	O
subsample	O
of	O
764	O
early	O
-	O
onset	O
bipolar	O
patients	O
and	O
2	O
,	O
938	O
matched	O
controls	O
from	O
the	O
United	O
Kingdom	O
out	O
of	O
the	O
WTCCC	O
,	O
were	O
either	O
directly	O
or	O
in	O
strong	O
linkage	O
disequilibrium	O
(	O
r2	O
>	O
0	O
.	O
99	O
)	O
with	O
SNPs	O
genotyped	O
in	O
the	O
WTCCC	O
sample	O
.	O

None	O
of	O
them	O
showed	O
a	O
nominal	O
P	O
-	O
value	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

However	O
,	O
two	O
SNPs	O
on	O
chromosome	O
5p13	O
in	O
lower	O
linkage	O
disequilibrium	O
(	O
r2	O
=	O
0	O
.	O
65	O
)	O
with	O
rs822135	O
showed	O
a	O
nominal	O
P	O
-	O
value	O
(	O
rs625487	O
,	O
P	O
=	O
0	O
.	O
02	O
,	O
OR	O
=	O
1	O
.	O
15	O
and	O
rs633407	O
,	O
P	O
=	O
0	O
.	O
02	O
,	O
OR	O
=	O
1	O
.	O
15	O
)	O
(	O
data	O
not	O
shown	O
).	O

Both	O
were	O
located	O
approximately	O
55	O
Kbp	O
upstream	O
to	O
PLCXD3	B-GP
and	O
165	O
Kbp	O
downstream	O
to	O
OXCT1	B-GP
.	O

In	O
addition	O
,	O
one	O
SNP	O
(	O
rs2565666	O
),	O
located	O
on	O
chromosome	O
12p12	O
,	O
21	O
Kbp	O
downstream	O
to	O
PLEKHA5	B-GP
and	O
42	O
Kbp	O
upstream	O
to	O
AEBP2	B-GP
,	O
also	O
showed	O
a	O
nominal	O
P	O
-	O
value	O
(	O
rs2565666	O
,	O
P	O
=	O
0	O
.	O
03	O
,	O
OR	O
=	O
1	O
.	O
22	O
)	O
(	O
data	O
not	O
shown	O
).	O

We	O
also	O
compared	O
a	O
sample	O
of	O
1	O
,	O
524	O
early	O
-	O
onset	O
bipolar	O
patients	O
with	O
1	O
,	O
436	O
controls	O
out	O
of	O
the	O
combined	O
GAIN	O
-	O
TGen	O
cohorts	O
.	O

None	O
out	O
of	O
the	O
15	O
tested	O
SNPs	O
showed	O
a	O
nominal	O
P	O
-	O
value	O
(	O
Table	O
S3	O
in	O
File	O
S2	O
).	O

The	O
mega	O
-	O
analysis	O
showed	O
a	O
high	O
heterogeneity	O
between	O
the	O
samples	O
from	O
France	O
and	O
Germany	O
and	O
the	O
two	O
samples	O
from	O
U	O
.	O
K	O
.	O
and	O
U	O
.	O
S	O
.	O
A	O
.	O

This	O
analysis	O
resulted	O
in	O
a	O
low	O
signal	O
on	O
chromosomes	O
5p13	O
and	O
12p12	O
(	O
rs10512793	O
,	O
Pmega	O
=	O
5	O
.	O
05	O
×	O
10	O
−	O
2	O
,	O
ORmega	O
=	O
1	O
.	O
38	O
and	O
rs3752823	O
,	O
Pmega	O
=	O
5	O
.	O
79	O
×	O
10	O
−	O
2	O
,	O
ORmega	O
=	O
1	O
.	O
43	O
,	O
respectively	O
).	O

The	O
strongest	O
association	O
observed	O
in	O
the	O
mega	O
-	O
analysis	O
for	O
SNPs	O
tested	O
in	O
at	O
least	O
three	O
of	O
the	O
four	O
populations	O
was	O
observed	O
on	O
chromosome	O
7q36	O
.	O
3	O
in	O
a	O
gene	O
desert	O
(	O
rs4716990	O
,	O
Pmega	O
=	O
3	O
.	O
78	O
×	O
10	O
−	O
2	O
,	O
ORmega	O
=	O
1	O
.	O
25	O
).	O

Structural	O
abnormalities	O
in	O
region	O
of	O
interest	O

Fluorescence	O
level	O
of	O
genotyped	O
SNPs	O
was	O
only	O
available	O
for	O
a	O
subsample	O
of	O
early	O
-	O
onset	O
patients	O
of	O
French	O
and	O
German	O
origin	O
(	O
N	O
=	O
321	O
).	O

We	O
analysed	O
this	O
fluorescence	O
level	O
in	O
the	O
two	O
1	O
.	O
5	O
Mbp	O
regions	O
of	O
interest	O
on	O
chromosome	O
5p13	O
and	O
12p12	O
.	O

On	O
chromosome	O
5p13	O
,	O
we	O
identified	O
,	O
in	O
a	O
French	O
patient	O
who	O
manifested	O
a	O
first	O
mood	O
episode	O
by	O
the	O
age	O
of	O
17	O
,	O
a	O
90	O
-	O
Kbp	O
deletion	O
removing	O
the	O
PLCXD3	B-GP
promoter	O
region	O
as	O
well	O
as	O
the	O
first	O
coding	O
exon	O
of	O
the	O
gene	O
(	O
Figure	O
2	O
),	O
whereas	O
no	O
copy	O
number	O
variation	O
has	O
been	O
previously	O
reported	O
in	O
this	O
region	O
in	O
the	O
database	O
of	O
genomic	O
variations	O
(	O
http	O
://	O
projects	O
.	O
tcag	O
.	O
ca	O
/	O
variation	O
/).	O

Although	O
DNA	O
was	O
not	O
available	O
for	O
first	O
-	O
degree	O
relatives	O
of	O
this	O
patient	O
,	O
the	O
deletion	O
was	O
confirmed	O
using	O
quantitative	O
PCR	O
analysis	O
(	O
data	O
not	O
shown	O
).	O

In	O
order	O
to	O
determine	O
whether	O
independent	O
family	O
specific	O
mutations	O
might	O
be	O
frequently	O
found	O
in	O
bipolar	O
patients	O
,	O
we	O
screened	O
all	O
coding	O
exons	O
of	O
PLCXD3	B-GP
in	O
334	O
French	O
subjects	O
(	O
204	O
patients	O
with	O
early	O
-	O
onset	O
BD	B-DS
and	O
130	O
patients	O
with	O
late	O
-	O
onset	O
BD	B-DS
).	O

Three	O
synonymous	O
variations	O
(	O
p	O
.	O
V58	O
,	O
p	O
.	O
A130	O
and	O
p	O
.	O
P251	O
)	O
were	O
found	O
in	O
these	O
patients	O
,	O
and	O
one	O
amino	O
acid	O
change	O
(	O
p	O
.	O
R93H	O
)	O
was	O
identified	O
in	O
one	O
subject	O
with	O
early	O
-	O
onset	O
BD	B-DS
type	I-DS
I	I-DS
and	O
obsessive	B-DS
compulsive	I-DS
disorder	I-DS
.	O

This	O
variation	O
was	O
not	O
found	O
in	O
293	O
unaffected	O
matched	O
controls	O
.	O

This	O
amino	O
acid	O
is	O
highly	O
conserved	O
through	O
evolution	O
and	O
,	O
according	O
to	O
PolyPhen	O
-	O
2	O
[	O
37	O
],	O
this	O
variation	O
is	O
predicted	O
to	O
strongly	O
affect	O
the	O
function	O
of	O
the	O
protein	O
.	O

Further	O
analysis	O
of	O
the	O
available	O
DNA	O
sample	O
in	O
this	O
family	O
showed	O
that	O
this	O
variation	O
was	O
transmitted	O
from	O
the	O
father	O
(	O
Figure	O
S3	O
in	O
File	O
S1	O
).	O

The	O
patient	O
manifested	O
first	O
mood	O
symptoms	O
by	O
the	O
age	O
of	O
19	O
.	O

Although	O
his	O
father	O
did	O
not	O
meet	O
criteria	O
for	O
mood	B-DS
disorder	I-DS
according	O
to	O
DSM	O
-	O
IV	O
,	O
his	O
first	O
cousin	O
manifested	O
major	B-DS
depressive	I-DS
disorder	I-DS
by	O
the	O
age	O
of	O
65	O
.	O

Unfortunately	O
,	O
no	O
DNA	O
was	O
available	O
for	O
this	O
subject	O
.	O

Copy	O
number	O
variation	O
identified	O
on	O
chromosome	O
5p13	O
.	O

(	O
A	O
)	O
Fluorescence	O
level	O
of	O
SNPs	O
of	O
the	O
region	O
for	O
the	O
deleted	O
patient	O
visualized	O
using	O
SnipPeep	O
.	O

Red	O
dots	O
represent	O
fluorescence	O
level	O
of	O
SNPs	O
and	O
green	O
dots	O
correspond	O
to	O
the	O
SNP	O
heterozygocity	O
.	O

(	O
B	O
)	O
Chromosomal	O
position	O
of	O
the	O
deletion	O
.	O

Gene	O
position	O
and	O
annotation	O
(	O
http	O
://	O
genome	O
.	O
ucsc	O
.	O
edu	O
/)	O
are	O
symbolised	O
by	O
green	O
arrows	O
.	O

Deletions	O
reported	O
in	O
the	O
Database	O
of	O
Genomic	O
Variants	O
(	O
http	O
://	O
projects	O
.	O
tcag	O
.	O
ca	O
/	O
variation	O
/)	O
are	O
represented	O
with	O
blue	O
bars	O
.	O

No	O
duplication	O
has	O
been	O
reported	O
in	O
this	O
region	O
.	O

A	O
red	O
bar	O
represents	O
the	O
deletion	O
identified	O
in	O
the	O
patient	O
with	O
early	O
-	O
onset	O
BD	B-DS
.	O

Discussion	O

The	O
important	O
clinical	O
heterogeneity	O
of	O
BD	B-DS
has	O
probably	O
hampered	O
the	O
identification	O
of	O
vulnerability	O
genes	O
so	O
far	O
.	O

After	O
tumultuous	O
starts	O
,	O
GWA	O
studies	O
have	O
enabled	O
the	O
identification	O
of	O
robust	O
and	O
replicable	O
genetic	O
findings	O
of	O
weak	O
effect	O
,	O
in	O
regions	O
of	O
CACNA1C	B-GP
,	O
ODZ4	B-GP
and	O
NCAN	B-GP
,	O
but	O
without	O
disease	O
specificity	O
[	O
4	O
].	O

In	O
this	O
study	O
,	O
we	O
conducted	O
a	O
genome	O
-	O
wide	O
approach	O
on	O
a	O
highly	O
heritable	O
phenotype	O
,	O
focusing	O
on	O
patients	O
with	O
an	O
early	O
age	O
at	O
onset	O
.	O

Based	O
on	O
the	O
genotyping	O
data	O
of	O
261	O
,	O
525	O
SNPs	O
,	O
we	O
did	O
not	O
identify	O
SNPs	O
that	O
reached	O
the	O
genome	O
-	O
wide	O
significant	O
threshold	O
in	O
our	O
patients	O
and	O
controls	O
of	O
French	O
origin	O
.	O

This	O
was	O
most	O
likely	O
due	O
to	O
the	O
small	O
sample	O
size	O
of	O
our	O
cohort	O
.	O

We	O
calculated	O
the	O
statistical	O
power	O
of	O
our	O
study	O
,	O
using	O
the	O
CaTS	O
software	O
[	O
38	O
]	O
and	O
estimated	O
that	O
we	O
had	O
80	O
%	O
chance	O
to	O
detect	O
only	O
SNPs	O
with	O
a	O
genetic	O
risk	O
factor	O
higher	O
than	O
1	O
.	O
7	O
(	O
Figure	O
S4	O
in	O
File	O
S1	O
).	O

However	O
,	O
recent	O
data	O
from	O
larger	O
cohort	O
studies	O
showed	O
a	O
polygenic	O
component	O
in	O
BD	B-DS
[	O
3	O
],	O
[	O
39	O
],	O
consistent	O
with	O
a	O
combine	O
vulnerability	O
resulting	O
from	O
many	O
variants	O
of	O
weak	O
effect	O
.	O

We	O
thus	O
conducted	O
a	O
replication	O
study	O
on	O
a	O
German	O
cohort	O
of	O
patients	O
with	O
early	O
-	O
onset	O
BD	B-DS
and	O
performed	O
a	O
subsequent	O
meta	O
-	O
analysis	O
.	O

Although	O
it	O
did	O
not	O
reach	O
the	O
genome	O
-	O
wide	O
significant	O
threshold	O
,	O
the	O
most	O
associated	O
region	O
in	O
our	O
meta	O
-	O
analysis	O
was	O
located	O
on	O
chromosome	O
12p12	O
.	O

This	O
region	O
has	O
been	O
previously	O
associated	O
with	O
bipolar	B-DS
disorder	I-DS
[	O
40	O
]–[	O
42	O
]	O
and	O
more	O
specifically	O
when	O
patients	O
had	O
an	O
early	O
age	O
at	O
onset	O
of	O
mania	B-DS
[	O
40	O
].	O

Five	O
SNPs	O
in	O
this	O
region	O
showed	O
a	O
difference	O
in	O
allele	O
frequencies	O
between	O
patients	O
and	O
controls	O
,	O
spanning	O
two	O
genes	O
,	O
PLEKHA5	B-GP
and	O
AEBP2	B-GP
.	O

The	O
genetic	O
refinement	O
using	O
imputed	O
data	O
showed	O
the	O
lowest	O
P	O
-	O
value	O
for	O
a	O
SNP	O
located	O
in	O
PLEKHA5	B-GP
(	O
rs10743315	O
,	O
P	O
=	O
2	O
.	O
1	O
×	O
10	O
−	O
7	O
).	O
PLEKHA5	B-GP
encodes	O
a	O
protein	O
containing	O
a	O
pleckstrin	B-GP
homology	O
domain	O
,	O
which	O
interacts	O
with	O
phosphatidylinositol	O
3	O
-	O
phosphate	O
[	O
43	O
].	O

Few	O
elements	O
are	O
known	O
about	O
this	O
gene	O
except	O
its	O
ubiquitous	O
pattern	O
of	O
expression	O
,	O
including	O
foetal	O
and	O
adult	O
brains	O
.	O

Nevertheless	O
,	O
there	O
is	O
compelling	O
evidence	O
for	O
the	O
implication	O
of	O
the	O
phosphatidylinositol	O
signalling	O
pathway	O
in	O
the	O
etiopathogeny	O
of	O
BD	B-DS
and	O
the	O
two	O
most	O
effective	O
mood	O
stabilisers	O
for	O
BD	B-DS
(	O
lithium	O
and	O
valproate	O
)	O
directly	O
inhibit	O
this	O
pathway	O
[	O
44	O
].	O

Further	O
exploration	O
of	O
response	O
to	O
mood	O
stabilizer	O
in	O
regards	O
to	O
the	O
PLEKHA5	B-GP
genotypes	O
might	O
help	O
in	O
understanding	O
the	O
difference	O
observed	O
according	O
to	O
the	O
patients	O
'	O
age	O
at	O
onset	O
[	O
15	O
].	O

The	O
second	O
most	O
associated	O
region	O
in	O
our	O
meta	O
-	O
analysis	O
was	O
located	O
on	O
chromosome	O
5p13	O
.	O

In	O
this	O
region	O
,	O
the	O
highest	O
difference	O
in	O
allele	O
frequencies	O
between	O
patients	O
with	O
early	O
-	O
onset	O
BD	B-DS
and	O
controls	O
was	O
observed	O
for	O
rs10512793	O
.	O

This	O
SNP	O
was	O
located	O
in	O
OXCT1	B-GP
,	O
which	O
encodes	O
a	O
3	B-GP
-	I-GP
oxoacid	I-GP
CoA	I-GP
transferase	I-GP
1	I-GP
.	O

This	O
enzyme	O
catalyzes	O
the	O
reversible	O
transfer	O
of	O
CoA	O
from	O
succinyl	O
-	O
CoA	O
to	O
acetoacetate	O
and	O
is	O
thus	O
the	O
first	O
step	O
of	O
ketone	O
body	O
utilization	O
,	O
the	O
main	O
source	O
of	O
lipid	O
-	O
derived	O
energy	O
for	O
the	O
brain	O
[	O
45	O
].	O

Mutations	O
in	O
this	O
gene	O
are	O
associated	O
with	O
succinyl	B-GP
CoA	I-GP
:	I-GP
3	I-GP
-	I-GP
oxoacid	I-GP
CoA	I-GP
transferase	I-GP
(	B-DS
SCOT	I-DS
)	I-DS
deficiency	I-DS
,	O
characterised	O
by	O
episodes	O
of	O
severe	O
ketoacidosis	O
[	O
46	O
],	O
[	O
47	O
],	O
which	O
can	O
also	O
emerge	O
during	O
treatment	O
with	O
some	O
atypical	O
antipsychotics	O
[	O
48	O
].	O

However	O
,	O
the	O
haplotype	O
analysis	O
of	O
this	O
region	O
suggested	O
that	O
the	O
associated	O
peak	O
might	O
be	O
located	O
more	O
likely	O
downstream	O
to	O
OXCT1	B-GP
and	O
upstream	O
to	O
PLCXD3	B-GP
.	O

This	O
result	O
is	O
consistent	O
with	O
the	O
90	O
Kbp	O
-	O
deletion	O
reported	O
in	O
one	O
of	O
the	O
French	O
patients	O
and	O
that	O
removed	O
the	O
promoter	O
region	O
and	O
the	O
first	O
coding	O
exon	O
of	O
PLCXD3	B-GP
.	O

Further	O
exploration	O
of	O
this	O
gene	O
revealed	O
a	O
mutation	O
predicting	O
to	O
change	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
protein	O
(	O
p	O
.	O
R93H	O
)	O
and	O
transmitted	O
from	O
his	O
father	O
,	O
who	O
had	O
a	O
first	O
cousin	O
with	O
major	B-DS
depressive	I-DS
disorder	I-DS
.	O

Interestingly	O
,	O
this	O
gene	O
encodes	O
a	O
phosphatidylinositol	B-GP
-	I-GP
specific	I-GP
phospholipase	I-GP
C	I-GP
,	O
strengthening	O
the	O
involvement	O
of	O
the	O
phosphoinositide	O
-	O
signalling	O
pathway	O
in	O
vulnerability	O
to	O
BD	B-DS
.	O

Note	O
that	O
tricyclic	O
antidepressants	O
(	O
e	O
.	O
g	O
.	O
desipramine	O
),	O
which	O
are	O
known	O
to	O
induce	O
rapid	O
cycling	O
or	O
induce	O
manic	B-DS
or	O
hypomanic	O
episodes	O
in	O
some	O
patients	O
with	O
BD	B-DS
[	O
49	O
],	O
stimulate	O
phospholipase	B-GP
C	I-GP
activity	O
and	O
the	O
production	O
of	O
the	O
second	O
messenger	O
inositol	O
1	O
,	O
4	O
,	O
5	O
-	O
trisphosphate	O
[	O
50	O
].	O

In	O
addition	O
,	O
experiments	O
performed	O
using	O
rat	B-OG
cultured	O
hippocampal	O
neurons	O
revealed	O
that	O
desipramine	O
rapidly	O
enhanced	O
the	O
spontaneous	O
SNAP25	B-GP
-	O
dependent	O
vesicular	O
release	O
of	O
glutamate	O
[	O
51	O
].	O

This	O
Ca2	O
+	O
dependent	O
mechanism	O
is	O
consistent	O
with	O
our	O
previously	O
reported	O
association	O
between	O
SNAP25	B-GP
and	O
early	O
-	O
onset	O
BD	B-DS
[	O
12	O
]	O
and	O
with	O
the	O
strong	O
associations	O
observed	O
between	O
SNPs	O
located	O
in	O
CACNA1C	B-GP
and	O
BD	B-DS
[	O
1	O
],	O
[	O
3	O
].	O

The	O
main	O
limitation	O
of	O
our	O
study	O
is	O
not	O
to	O
reach	O
the	O
stringent	O
genome	O
-	O
wide	O
threshold	O
.	O

Although	O
this	O
might	O
translate	O
an	O
absence	O
of	O
common	O
genetic	O
variations	O
for	O
a	O
clinical	O
subgroup	O
based	O
on	O
an	O
early	O
age	O
at	O
onset	O
,	O
this	O
is	O
also	O
a	O
direct	O
consequence	O
of	O
the	O
small	O
sample	O
size	O
and	O
the	O
loss	O
of	O
power	O
inherent	O
to	O
the	O
subphenotype	O
analysis	O
.	O

Similar	O
study	O
on	O
larger	O
sample	O
should	O
be	O
performed	O
to	O
confirm	O
our	O
data	O
and	O
valid	O
the	O
relevance	O
of	O
such	O
approach	O
.	O

Nevertheless	O
,	O
results	O
observed	O
in	O
our	O
French	O
subsample	O
with	O
an	O
early	O
age	O
at	O
onset	O
have	O
been	O
replicated	O
in	O
a	O
German	O
sample	O
and	O
supported	O
by	O
the	O
data	O
from	O
the	O
WTCCC	O
with	O
similar	O
phenotype	O
criteria	O
.	O

Another	O
possible	O
cause	O
of	O
the	O
loss	O
of	O
power	O
in	O
our	O
analysis	O
is	O
the	O
categorical	O
exploration	O
of	O
the	O
age	O
at	O
onset	O
.	O

Despite	O
a	O
widely	O
valid	O
threshold	O
for	O
the	O
age	O
at	O
onset	O
[	O
16	O
],	O
[	O
17	O
],	O
[	O
22	O
]–[	O
25	O
],	O
a	O
continuous	O
exploration	O
of	O
this	O
variable	O
would	O
allow	O
to	O
determine	O
whether	O
specific	O
loci	O
might	O
lead	O
to	O
various	O
age	O
at	O
onset	O
,	O
which	O
would	O
result	O
,	O
under	O
multiplicative	O
or	O
additive	O
models	O
,	O
in	O
an	O
overall	O
early	O
age	O
-	O
at	O
-	O
onset	O
in	O
patients	O
.	O

Such	O
hypothesis	O
is	O
supported	O
by	O
the	O
recent	O
observation	O
of	O
the	O
International	O
Schizophrenia	B-DS
Consortium	O
,	O
which	O
showed	O
the	O
molecular	O
genetic	O
evidence	O
for	O
a	O
substantial	O
polygenic	O
component	O
to	O
the	O
risk	O
of	O
BD	B-DS
involving	O
thousands	O
of	O
common	O
alleles	O
of	O
very	O
small	O
effect	O
[	O
39	O
].	O

Similar	O
analysis	O
should	O
thus	O
be	O
performed	O
according	O
to	O
the	O
patients	O
'	O
age	O
at	O
onset	O
,	O
but	O
this	O
should	O
require	O
larger	O
samples	O
for	O
the	O
study	O
and	O
the	O
replication	O
analysis	O
.	O

In	O
conclusion	O
,	O
although	O
we	O
did	O
not	O
reach	O
the	O
genome	O
-	O
wide	O
significant	O
threshold	O
in	O
our	O
association	O
study	O
,	O
we	O
report	O
here	O
convergent	O
data	O
between	O
our	O
GWA	O
study	O
on	O
early	O
onset	O
BD	B-DS
,	O
the	O
structural	O
abnormality	O
observed	O
in	O
one	O
patient	O
and	O
a	O
missense	O
mutation	O
reported	O
in	O
one	O
family	O
with	O
early	O
-	O
onset	O
BD	B-DS
.	O

The	O
difficulties	O
to	O
reach	O
the	O
stringent	O
genome	O
-	O
wide	O
significant	O
threshold	O
suggest	O
that	O
larger	O
samples	O
should	O
be	O
included	O
,	O
which	O
will	O
also	O
help	O
in	O
better	O
defining	O
the	O
most	O
convenient	O
strategy	O
to	O
take	O
into	O
account	O
the	O
age	O
at	O
onset	O
of	O
patients	O
.	O

Although	O
the	O
current	O
nominally	O
significant	O
findings	O
should	O
be	O
interpreted	O
with	O
caution	O
and	O
need	O
replication	O
in	O
independent	O
cohorts	O
,	O
our	O
results	O
displayed	O
that	O
the	O
combined	O
exploration	O
of	O
common	O
and	O
rare	O
variants	O
in	O
BD	B-DS
can	O
reveal	O
identical	O
pathways	O
suggesting	O
both	O
approaches	O
should	O
be	O
systematically	O
used	O
in	O
further	O
genetic	O
exploration	O
of	O
this	O
disorder	O
.	O

Using	O
these	O
approaches	O
,	O
we	O
provided	O
evidence	O
that	O
variations	O
in	O
phosphoinositide	O
secondary	O
messenger	O
signalling	O
pathway	O
,	O
and	O
for	O
the	O
first	O
time	O
,	O
that	O
the	O
PLEKHA5	B-GP
and	O
PLCXD3	B-GP
genes	O
,	O
might	O
confer	O
vulnerability	O
to	O
early	O
-	O
onset	O
BD	B-DS
.	O

Further	O
exploration	O
of	O
these	O
mechanisms	O
might	O
be	O
used	O
to	O
better	O
identify	O
markers	O
of	O
prognosis	O
and	O
help	O
the	O
development	O
of	O
innovative	O
treatment	O
for	O
these	O
severe	O
forms	O
of	O
the	O
disease	O
.	O

Supporting	O
Information	O

Contains	O
Tables	O
S1	O
-	O
S2	O
and	O
Figures	O
S1	O
-	O
S4	O
.	O

(	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Contains	O
Table	O
S3	O
.	O

(	O
XLSX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

